Literature DB >> 25099191

Aging hemostasis: changes to laboratory markers of hemostasis as we age - a narrative review.

Emmanuel J Favaloro1, Massimo Franchini2, Giuseppe Lippi3.   

Abstract

The incidence of venous thromboembolism (VTE) is well recognized to increase with aging. Concurrently, the plasma concentrations of many coagulation factors (e.g., fibrinogen, factor [F] V, FVII, FVIII, and FIX) increase with aging, as does von Willebrand factor (VWF), thrombin generation, and platelet activation. Data are conflicting regarding age-related changes in the natural anticoagulants, including protein C, protein S, and antithrombin. Changes are also observed with components of the fibrinolytic pathway. All in all, aging is associated with a variety of hemostasis changes that on balance reflects a heightened procoagulant status compared with earlier age. It has to be recognized that as this occurs in the otherwise normal general population, this can also be considered a normal phenomenon of progressive life. An element of this heightened procoagulant status may reflect ongoing inflammatory processes, given some markers, notably FVIII and fibrinogen, are acute phase reactants. A variety of acquired prothrombotic risk factors (e.g., cancer, autoimmune disorders, and diabetes) also gradually develop with aging, some of which may induce profound abnormalities of hemostasis, and confound the age-related changes in hemostasis, as well as their influence on thrombotic risk. In this article, we review the changes in hemostasis markers measurable within many hemostasis laboratories, and consider many of the important implications for clinical and laboratory practice. Apart from representing an increased thrombotic risk, additional considerations entail the potential need (1) to utilize age-adjusted normal ranges (e.g., for D-dimer), (2) to consider the consequence on previous diagnoses (e.g., "mild type 1" von Willebrand disease [VWD], where VWF test results may "normalize" with aging), and (3) to consider the effect of these changes of risk factors on the (perceived) therapeutic efficacy of antithrombotic medications such as aspirin. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25099191     DOI: 10.1055/s-0034-1384631

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  38 in total

1.  Combined Inflammation and Metabolism Biomarker Indices of Robust and Impaired Physical Function in Older Adults.

Authors:  Xintong Zuo; Alison Luciano; Carl F Pieper; James R Bain; Virginia B Kraus; William E Kraus; Miriam C Morey; Harvey J Cohen
Journal:  J Am Geriatr Soc       Date:  2018-05-08       Impact factor: 5.562

2.  More or less living according to your blood type.

Authors:  Leonardo Pasalic; Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2014-12-17       Impact factor: 3.443

3.  Altered functions of platelets during aging.

Authors:  Emilie Montenont; Matthew T Rondina; Robert A Campbell
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

4.  Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?

Authors:  Mariachiara Borghi; Giuseppe Guglielmini; Anna Maria Mezzasoma; Emanuela Falcinelli; Loredana Bury; Marco Malvestiti; Paolo Gresele
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

5.  Translational aspects of developmental hemostasis: infants and children are not miniature adults and even adults may be different.

Authors:  Emmanuel J Favaloro; Giuseppe Lippi
Journal:  Ann Transl Med       Date:  2017-05

6.  Imaging of the venous plexus of Rektorzik using CT-digital subtraction venography: a retrospective study.

Authors:  Ryotaro Imai; Katsuhiro Mizutani; Takenori Akiyama; Takashi Horiguchi; Yoshifumi Takatsume; Masahiro Toda
Journal:  Neuroradiology       Date:  2022-04-22       Impact factor: 2.995

Review 7.  Are microparticles the missing link between thrombosis and autoimmune diseases? Involvement in selected rheumatologic diseases.

Authors:  Melissa Cunningham; Natalia Marks; April Barnado; Jena R Wirth; Gary Gilkeson; Margaret Markiewicz
Journal:  Semin Thromb Hemost       Date:  2014-08-31       Impact factor: 4.180

8.  Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.

Authors:  Anwar Al-Awadhi; Adekunle Adekile; Rajaa Marouf
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

9.  Self-Reported Sitting Time, Physical Activity and Fibrinolytic and Other Novel Cardio-Metabolic Biomarkers in Active Swedish Seniors.

Authors:  Bethany J Howard; Anita Hurtig-Wennlöf; Lovisa A Olsson; Torbjörn K Nilsson; David W Dunstan; Patrik Wennberg
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

10.  Reasons for Exclusion of Apparently Healthy Mature Adult and Senior Dogs From a Clinical Trial.

Authors:  Nicole H Gibbs; Hannah Michalski; Daniel E L Promislow; Matt Kaeberlein; Kate E Creevy
Journal:  Front Vet Sci       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.